Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Subscribe to Free Drug Patent Expiration Updates

Also available in a Drug Patent Expiration NewsletterRSS feed and on Drug Patent Expirations on TwitterTwitter

DrugPatentWatch Archives

You are currently viewing the 2000 archives
Click here to return to the current data set

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: NEMBUTAL

« Back to Dashboard
Nembutal is a drug marketed by Oak Pharms and is included in six NDAs.

The generic ingredient in NEMBUTAL is pentobarbital sodium. There are two drug master file entries for this compound. Additional details are available on the pentobarbital sodium profile page.

Summary for Tradename: NEMBUTAL


Clinical Trials for: NEMBUTAL

Dexmedetomidine Versus Pentobarbital for Pediatric Procedural Sedation
Status: Withdrawn Condition: Sedation

Comparison of Effectiveness of Pentobarbital and Thiopental in Patients With Refractory Intracranial Hypertension
Status: Terminated Condition: Traumatic Brain Injury

A Comparison of Two Sedation Techniques in Children Undergoing Transthoracic Echocardiography (TTE)
Status: Recruiting Condition: Heart Disease

Sedation for Brainstem Evoked Auditory Response (BEAR) Testing Using Intravenous Pentobarbital
Status: Completed Condition: Childrens 0 to 18 Years of Age Who Require Moderate Sedation

GHB Withdrawal Symptoms and Effectiveness of Treatment With Lorazepam Versus Pentobarbital - 1
Status: Terminated Condition: Sodium Oxybate; Substance-Related Disorders

Physiological, Behavioral and Subjective Effects of Drugs (GHB)
Status: Completed Condition: Sedative Abuse

Pharmacokinetics and Pharmacodynamics of Pentobarbital in Neonates, Infants, and Children Following Open Heart Surgery
Status: Terminated Condition: Cardiac Surgical Procedures

Treatment of Refractory Status Epilepticus
Status: Terminated Condition: Status Epilepticus

Mutations in Genes Associated With Pentalogy of Cantrell or Non-Muscle Myosin II Syndromes
Status: Recruiting Condition: Inborn Genetic Diseases; Pentalogy of Cantrell

A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users
Status: Completed Condition: Alzheimer's Disease; Huntington's Disease

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Exclusivity Expiration
Elixir; Oral083244-001Approved prior to Jan 1, 1982RXYes<disabled><disabled>
pentobarbital sodium
Injectable; Injection083246-001Approved prior to Jan 1, 1982RXYes<disabled><disabled>
pentobarbital sodium
Suppository; Rectal083247-003Jan 25, 1982RXYes<disabled><disabled>
pentobarbital sodium
Capsule; Oral084093-001Approved prior to Jan 1, 1982RXYes<disabled><disabled>
pentobarbital sodium
Suppository; Rectal083247-001Jan 25, 1982RXYes<disabled><disabled>
This preview shows a limited data set
Subscribe for full access

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a free trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn